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Mutations in FEZF1 Cause Kallmann Syndrome
L. Damla Kotan,1,7 B. Ian Hutchins,2,7 Yusuf Ozkan,3 Fatma Demirel,4 Hudson Stoner,2 Paul J. Cheng,2
Ihsan Esen,4 Fatih Gurbuz,5 Y. Kenan Bicakci,6 Eda Mengen,5 Bilgin Yuksel,5 Susan Wray,2,*
and A. Kemal Topaloglu1,5,*
Gonadotropin-releasing hormone (GnRH) neurons originate outside the CNS in the olfactory placode and migrate into the CNS, where
they become integral components of the hypothalamic-pituitary-gonadal (HPG) axis. Disruption of this migration results in Kallmann
syndrome (KS), which is characterized by anosmia and pubertal failure due to hypogonadotropic hypogonadism. Using candidate-gene
screening, autozygositymapping, and whole-exome sequencing in a cohort of 30 individuals with KS, we searched for genes newly asso-
ciated with KS. We identified homozygous loss-of-function mutations in FEZF1 in two independent consanguineous families each with
two affected siblings. The FEZF1 product is known to enable axons of olfactory receptor neurons (ORNs) to penetrate the CNS basal
lamina in mice. Because a subset of axons in these tracks is the migratory pathway for GnRH neurons, in FEZF1 deficiency, GnRH
neurons also fail to enter the brain. These results indicate that FEZF1 is required for establishment of the central component of the
HPG axis in humans.Kallmann syndrome (KS [MIM 308700, 147950, 244200,
610628, 612370, and 612702]) is characterized by a combi-
nation of hypogonadotropic hypogonadism and anosmia.
This pathophysiological association results from a defect in
the shared development of gonadotropin-releasing hor-
mone (GnRH) neurons and olfactory neurons.1,2 Both
types of neurons originate in the nasal placode, and
GnRH neurons migrate in association with olfactory
axon bundles to the CNS. Upon entering the CNS, olfac-
tory axons synapse in the olfactory bulb, whereas GnRH
neurons migrate caudally on a subset of nonsensory olfac-
tory axons to reach the hypothalamus. Once within the
hypothalamus, GnRH neurons form a functional network,
producing pulsatile GnRH secretion. Disruption of this
migration results in KS. A number of genes have been
implicated to cause KS when mutated. These include
KAL13,4 (MIM 308700), genes involved in the fibroblast
growth factor (FGF) signaling pathway (FGF8 [MIM
600483], FGFR1 [MIM 136350], FGF17, IL17RD,
DUSP6, SPRY4, and FLRT3),5–7 genes associated with the
PROK2 signaling pathway (PROK2 [MIM 607002] and
PROKR2 [MIM 607123]),8,9 CHD710 (MIM 608892),
WDR1111 (MIM 614858), SEMA3,12,13 SOX10,14 and
HS6ST115 (MIM 614880). Mutations in these genes ac-
count for less than half of all familial cases, and thus iden-
tification of newly associated genes is highly likely, which
could provide insight into the biology of GnRH neuronal
migration.16 Here, we describe two independent consan-
guineous families in which the KS phenotype is associated
with loss-of-function mutations in FEZF1.
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326 The American Journal of Human Genetics 95, 326–331, Septembinformed consent was obtained for each participant. A
cohort of 30 individuals was studied in an effort to identify
a gene newly associated with KS. In this prospective, multi-
center study, the diagnosis of KS was based on the presence
of anosmia and the absence of any signs of spontaneous
puberty by 13 years of age in girls (Tanner breast stage 1)
and by 14 years of age in boys (testicular volume <
4 ml), as well as concentrations of sex steroids at inappro-
priately normal hypogonadal levels or low gonadotropin
levels. There were five consanguineous multiplex families
with more than one affected individual. The rest of the
cohort consisted of single affected persons. Those multi-
plex families were prioritized and screened first for muta-
tions in the known KS-associated genes. In one of the
multiplex families (family 1), a 19-year-old male (II-3) pre-
sented first with absent pubertal development at age 14
years. He received testosterone and human chorionic
gonadotropin (HCG) treatments and underwent surgery
for undescended testicles. His penis developed to normal
adult size with testosterone treatment, but his testicles re-
mained small. His 24-year-old sister (II-1) suffered from
absent breast development and primary amenorrhea.
Only after starting estrogen replacement at age 18 did
her breast development and subsequent menstrual periods
begin. In a second multiplex family (family 2), a 14-year-
old male (II-2) presented first with micropenis and unde-
scended testicles at age 2 years. For undescended testicles,
he received repeated HCG treatments; upon failure, he was
subsequently operated on. He has not had any sponta-
neous pubertal development, for which he was given
testosterone injections. Currently, he has 1 ml of testicles
bilaterally and 4 cm of phallus with stage 2 axillary and1330 Adana, Turkey; 2Cellular and Developmental Neurobiology Section,
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Table 1. Hormonal Results of the Affected Siblings when They
Were off Hormonal Treatment
Family 1 Family 2
Normal RangeII-1 II-3 II-2 II-4
Sex F M M M –
Age (years) 24 19 14 8 –
FSH (mIU/ml) 0.6 0.1 0.1 0.6 M: 1.4–18.1
F: 2.5–10.2
LH (mIU/ml) 0.1 0.1 0.1 0.1 M: 1.5–9.3
F: 1.9–12.5
Estradiol (ng/dl) 0.7 ND ND ND M: 0.8–3.5
F: 6.3–16.5
Testosterone (ng/dl) ND 69.0 20.0 10.0 M: 175–781
F: 20–38
Prolactin (ng/ml) 8.9 6.6 ND ND M: 2.1–17.7
F: 2.8–29.2
TSH (mIU/ml) 1.1 2.8 2.1 2.0 0.35–4.2
Free T4 (ng/dl) 0.8 1.1 1.0 1.1 0.89–1.8
ACTH (pg/ml) 34.8 9.1 ND ND 5–55
Cortisol (mcg/dl) 21.2 12.9 ND ND 3–25








– – 1.3 – M: 1.4–18.1
F: 2.5–10.2
The coefficients of variation within assays and between assays were less
than 5%. Abbreviations are as follows: ACTH, adrenocorticotropic hormone;
DHEAS, dehydroepiandrosterone; F, female; FSH, follicle-stimulating hor-
mone; LH, luteinizing hormone; LHRH, luteinizing-hormone-releasing hor-
mone; M, male; ND, not determined; T4, thyroxine; and TSH, thyroid-stimu-
lating hormone.pubic hair. A recent GnRH stimulation test elicited a prepu-
bertal response with a maximum luteinizing hormone
response of 0.2 mIU/ml. His 8-year-and-7-month-old
male sibling (II-4) also has micropenis and undescended
testicles, for which he received an operation at 2 years of
age after failure of repeated HGC treatment. Currently,
he is prepubertal with 1 ml of testicles bilaterally and
3.6 cm of phallus with stage 1 axillary and pubic hair.
Both families are ethnically Kurdish from distant provinces
and are not knowingly related to each other. None of the
parents or other siblings has experienced problems in
pubertal development or fertility. All four individuals
from both families are otherwise healthy. They do not
have mental disorders, dysmorphic facial features (such
as cleft lip, cleft palate, or hypodontia), bone anomalies,
deafness, renal agenesis, or bimanual synkinesia, which
are sometimes associated with KS.16 They all have
anosmia, documented by a quantitative smell-identifica-
tion test. Olfactory function of both the proband and his
unaffected brother (II-2) in family 1 was evaluated with
the 40-item University of Pennsylvania smell-identifica-
tion test (UPSIT). The UPSIT is a validated microencapsu-The Americanlated odor scratch-and-sniff test that correlates with other
olfactory tests, including odor-detection thresholds.17 To
control for cross-cultural variation of smell identification,
we also administered a culturally appropriate 20-item smell
test. Results of this test were found to be consistent with
the UPSIT results. The culturally appropriate 20-item smell
test was also administered to the proband in family 2. The
hormonal profiles of all four individuals when they were
off treatment are shown in Table 1. Brain-MRI studies of
the probands showed bilateral aplasia of the olfactory
bulbs (Figure 1B).
We first ruled out mutations in known KS-associated
genes, including KAL1, FGFR1, FGF8, PROK2, PROKR2,
CHD7, WDR11, and HS6ST1, by Sanger sequencing on
an Applied Biosystems PRISM 3130 autosequencer. Subse-
quently, we combined autozygosity mapping and exome
sequencing. A genome-wide SNP analysis used 250K
NspI SNP microarrays (Affymetrix), and the data were
analyzed with AutoSNPa software. For exome sequencing,
samples were prepared as an Illumina sequencing library.
Sequencing libraries were enriched with the desired target
according to the Illumina Exome Enrichment protocol.
The captured libraries were sequenced with the Illumina
HiSeq 2000 Sequencer. The reads were mapped against
the UCSC Genome Browser (hg19). In family 1, autozygos-
ity mapping identified three regions of homozygosity: a
5.8 Mb region from 165.7 to 171.5 Mb on chromosome
1, a 7.7Mb region from 172.4 to 180.1Mb on chromosome
2, and a 12 Mb region from 110.7 to 122.4 Mb on chromo-
some 7. Whole-exome sequencing data, which were
filtered with the ‘‘rare recessive Mendelian disease’’ mode
in wANNOVAR, indicated two homozygous mutations
each located within these homozygous regions. The
FEZF1 (FEZ family zinc finger 1 [MIM 613301]) mutation,
which was located in the homozygous region on chromo-
some 7, involved a C-to-T change (c.832C>T [RefSeq acces-
sion number NM_001024613.2]) leading to p.His278Tyr
(RefSeq NP_001019784.2). Both affected siblings were
homozygous for this mutation, and the parents and unaf-
fected siblings (except for II-4, who was homozygous for
the wild-type) were heterozygous (Figure S1, available
online). This mutation changes the first histidine in the
well-known C2H2 motif, which is required for the stability
of the central zinc in zinc-finger proteins.18 Therefore, this
residue is extremely evolutionarily conserved, and all vari-
ants are predicted to be deleterious.
The other variant was a nonsense mutation (c.2270C>T
[p.Arg724*]) in CCDC141 and was located in the homozy-
gous region on chromosome 2. Both individuals were
homozygous for the change, and the parents and unaf-
fected siblings were all heterozygous.
The four multiplex families in the KS cohort were priori-
tized forexomesequencing. Inoneof the families (family2),
we found an additional FEZF1 mutation (c.652del) result-
ing in a frameshift and premature stop (p.Ala217fs*13)
(Figure S1). Transcripts harboring this frameshift mutation
might be sensitive to nonsense-mediated mRNA decay.19Journal of Human Genetics 95, 326–331, September 4, 2014 327
Figure 1. Pedigree and Olfactory MRI of the Probands
(A) Pedigrees of the families; arrows point to probands. Solid symbols indicate affected family members, open symbols indicate
unaffected family members, squares indicate male family members, circles indicate female family members, and the double line indi-
cates consanguinity. Under each symbol is the FEZF1 genotype.
(B) BrainMRI at T2 coronal sections. The left panel is from a healthy young adult; the arrow indicates normal olfactory bulbs. Themiddle
panel shows the absence of olfactory bulbs (aplasia) in the proband from family 1. The right panel demonstrates the absence of olfactory
bulbs (aplasia) in the proband from family 2.Whereas all affected siblingswerehomozygous for c.652del,
both parents and unaffected siblings were heterozygous.
None of the individuals from family 2 carried mutations
in CCDC141. No additional probands from the KS cohort
had mutations in FEZF1 or CCDC141. The inheritance
pattern in both families was consistent with autosomal-
recessive inheritance. In view of the oligogenic inheri-
tance repeatedly reported in KS,8,12,20 we attempted to
ensure that all variants were identified to account for
the KS phenotype by combining a variety of genetics
methods, including candidate-gene screening, autozygos-
ity mapping, and whole-exome sequencing. FEZF1 muta-
tions in this study were not found in public SNP databases
(dbSNP136, 1000 Genomes, or the NHLBI Exome
Sequencing Project Exome Variant Server). Additionally,
neither of the mutations was seen in 100 ethnically
matchedhealthyadult control individualsor in36 in-house
whole exomes.
To determine the predicted consequences of the muta-
tions on FEZF1 function, we used in silico prediction
methods and 3D molecular modeling. PolyPhen-2, SIFT,
and MutationTaster indicated that both mutations would
be harmful. Using the SWISS-MODEL protein-structure
homology-modeling server to evaluate the domains sur-
rounding the altered residues indicated that changes to
the secondary structure are not predicted, although the
stability of the zinc binding structure could be affected.328 The American Journal of Human Genetics 95, 326–331, SeptembTo assess the transcriptional activity of FEZF1, we trans-
fected human embryonic kidney 293T cells with wild-type
and mutant (c.832C>T) plasmids (GeneArt) together with
a Hes5p-DsRed reporter. This reporter is known to be
repressed by FEZF1 during early cortical neurogenesis.21
Wild-type FEZF1 reduced DsRed accumulation, as mea-
sured by immunoblot (Figures 2C and 2D); however, the
FEZF1 mutant accumulated intermediate levels of DsRed,
indicating a partial loss of function.
All together, in a cohort of 30 probands with KS, we
found deleterious homozygous FEZF1 variants in two inde-
pendent consanguineous families each with two siblings
afflicted with severe KS, including complete hypogonado-
tropic hypogonadism and anosmia and absent olfactory
bulbs. KS is genetically heterogeneous and has various
modes of transmission and oligogenic inheritance.22 In
contrast to previously described KS-associated gene de-
fects, such as mutations in FGFR15 or PROKR2,8,9 the
phenotypical features in our subjects were invariably
severe, and heterozygous parents and siblings had nor-
mal reproductive and olfactory functions; thus, the mode
of inheritance is solely autosomal-recessive in families
affected by FEZF1 mutations. The presence of micropenis
and cryptorchidism in the male individuals reflects com-
plete hypogonadotropic hypogonadism since intrauterine
life.23 The absence of additional phenotypical features
(such as cleft palate, deafness, and synkinesia, which caner 4, 2014
Figure 2. Functional Analysis of Mutated
FEZF1
(A) Predicted 3D model of the zinc-finger
domain containing histidine 278. Histi-
dine residues (blue) are shown alongside
cysteine (yellow) and bound zinc.
(B) Predicted 3D model of the altered
FEZF1, in which histidine 278 changed to
a tyrosine, from family 1.
(C) Analysis of DsRed band optical density
(normalized to tubulin) with either no
FEZF1, altered FEZF1, or wild-type FEZF1.
Histograms show the mean, and error
bars represent the SE (*p < 0.05,
repeated-measures one-way ANOVA with
the Holm-Sidak posttest).
(D) Example of an immunoblot showing
Hes5-DsRed levels when cotransfected
with no FEZF1 (left), altered FEZF1 (middle), or wild-type FEZF1 (right). Immunoblot analysis was performed according to standard
protocols. Protein was extracted 24 hr after transfection. Fifty micrograms of total protein was denatured, subsequently loaded into a
7.5% gel, and then separated. Protein was then transferred to a polyvinylidene fluoride membrane, blocked, and incubated in primary
antibody overnight. Then the membranes were washed, subsequently incubated with horseradish-peroxidase-conjugated secondary
antibody for 2 hr, and visualized with an enhanced chemiluminescence reaction. Band density was quantified with ImageJ. DsRed
band density was normalized to b-tubulin levels. Rabbit anti-human ZNF312B (FEZF1, Abcam, catalog no. ab81251, 1:1,000), anti-DsRed
(Clontech, catalog no. 632496, 1:1,000), mouse anti-b-tubulin (Sigma, catalog no. T4026, 1:1,000), anti-rabbit HRP (Cell Signaling,
catalog no. 7074, 1:5,000), anti-mouse HRP (Cell Signaling, catalog no. 7076, 1:5,000) antibodies were used in these experiments.
Statistical significance was determined with Prism (GraphPad).be seen in other KS-associated gene mutations5,8,9) sug-
gests that FEZF1 is spatially and temporally restricted in
expression and functionally specific. Consistency among
these phenotypical features of FEZF1-associated KS might
not hold in additional future mutations, given that the
affected individuals in this study probably represent the
most severe cases. In one of the families (family 1), we
found a second homozygous mutation in another gene,
CCDC141, whose gene product has been implicated in
cortical neuronal migration,24 and this mutation might
cause additional detrimental effects.
FEZF1 is a zinc-finger gene encoding a transcriptional
repressor that is highly and selectively present during
embryogenesis in the olfactory epithelium, amygdala,
and hypothalamus. Interestingly, these tissues and organs
mark the pheromone pathway from the nose to the GnRH
pulse generator in the hypothalamus.25–28 Two indepen-
dent studies have shown that Fezf1-deficient mice have
impaired axonal projection of pioneer olfactory receptor
neurons (ORNs) that cross the cribriform plate and subse-
quently innervate the olfactory bulb. This defect was
attributed to the inability of ORN axons to penetrate the
basal lamina of the CNS. These mice have smaller olfactory
bulbs and an absence of GnRH neurons in the brain.27,29
When these experiments were repeated with the basal lam-
ina surgically removed, GnRH neurons were found to be in
their expected locations in the hypothalamus.27 Thus, it
seems likely that the FEZF1 product promotes the presence
of a protease to enable ORNs, and thus accompanying
GnRH neurons, to enter the brain.27,30 Upon entering
the CNS, ORN axons make synapses with olfactory bulb
neurons, which is believed to promote the development
of the olfactory bulbs.31 Thus, the absence of olfactory
bulbs on MRI in humans with KS indicates a strong paral-The Americanlelism with the rodent data in that ORNs fail to penetrate
the basal lamina and subsequently induce the growth of
the olfactory bulbs. Fezf1-knockout mice in both studies
died early postnatally with abdominal distention, so their
puberty and fertility could not be observed. Our findings in
humans suggest that hypogonadism associated with a
GnRH-migration deficit due to FEZF1 mutations cannot
be compensated by some other mechanism, although,
again, it should be noted that the affected individuals in
this study are likely to be the most severe cases.
This study highlights a step in deciphering the molecu-
lar mechanisms involved in the development of the
GnRH neuronal system. The nasal-forebrain junction is a
crucial point in the migration of GnRH neurons, and
crossing of this junction is a finely regulated step in which
different players act together in a coordinated manner to
guide the entrance of these neurons into the forebrain.32
However, it should be kept in mind that other sites of em-
bryonic expression (i.e., the amygdala and hypothala-
mus)25–27 might also be involved in the pathogenesis of
FEZF1-associated KS. Also, in this regard, it is important
to note that the potential genes up- or downregulated by
FEZF1 remain to be identified.
The potential mechanism of KS due to FEZF1mutations
appears to be different from those of previously described
causes of KS. Fibroblast growth factor signaling, prokineti-
cin signaling, and anosmin-1, defects of which constitute
the great majority of KS cases, appear to interact with
heparin sulfate glycosominoglycan compounds within
an extracellular signaling complex in promoting GnRH
neuronal migration.5,22 WDR11 mutations could be the
only previously implicated cause of KS that can be in any
way likened to FEZF1 deficiency. The WDR11 product is
known to interact with transcription factor emx1,11 whoseJournal of Human Genetics 95, 326–331, September 4, 2014 329
paralog (emx2) is involved in innervation of the olfactory
bulb by ORNs in mice.33
In conclusion, the FEZF1 mutations reported here are
examples of genetic aberrations accounting for KS. These
studies strongly suggest that in humans, FEZF1 plays a
role in embryonic migration of GnRH neurons into the
brain to eventually form a hypothalamic neuronal
network essential for pulsatile GnRH secretion and thus
puberty and fertility.Supplemental Data
Supplemental Data include one figure and can be found with this
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